Illuminate PD1/PD-L1 Interactions:

Unlocking the potential of immune checkpoint inhibition therapy calls for precise patient stratification ^1-3. While PD-L1 is a commonly used biomarker, its correlation with immunotherapy outcomes isn’t always linear³. Addressing this challenge, Navinci expands its portfolio to unravel PD1 signaling, introducing the groundbreaking fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N.

With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of immune checkpoint activation.

If you prefer to detect PD1/PD-L1 using bright-field, we have you covered with our chromogenic assays. Choose from our range of assays to suit your specific research needs and explore the PD1 signaling pathway.

Download white paper: Identifying PD-1/PD-L1 interactions  –  Implications for clinical research and ICI patient stratification(pdf)

PD1/PD-PL1 interaction

Naveni PD1/PD-L1 HRP

Naveni PD1/PD-L1 AP

Naveni PD1/PDL1 Atto647N

Phosphorylated PD1

Naveni pY PD1 HRP

Naveni pY PD1 AP

The Naveni PD1/PD-L1 kits are based on our proprietary Naveni^TM Proximity Ligation Technology. The kits include two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct dot. Naveni PD1/PD-L1 Atto647N is compatible with IF co-staining.